Latest Leadership Changes News

Elanor Investors Group appoints David McNamara as CEO, signaling a leadership shift following a balance sheet recapitalisation and strategic reset. The Board also sees key transitions with Tony Fehon moving to a non-executive role and Su Kiat Lim stepping down.

Promisia Healthcare reported a 58% jump in underlying EBITDAF to $6.6 million for FY26, driven by improved occupancy and operational upgrades. The company introduced a dividend policy tied to operating free cash flow, signalling confidence in sustained cash generation.

ImpediMed has revamped its leadership with two new commercial roles and reported encouraging sales momentum for its SOZO device. The company is advancing clinical trials and expanding its presence in cancer survivorship, weight management, and heart health sectors.

Resouro Strategic Metals has locked in a binding agreement with Future Mining and Buri Gold to fund and operate mining and processing at its Novo Mundo gold project in Brazil, aiming to generate cash flow without diverting capital from its flagship Tiros project.

Spenda Limited (ASX: SPX) has voluntarily suspended trading of its shares from 2 June 2026 to manage disclosure around its institutional accelerated renounceable entitlement offer (AREO). The suspension is expected to last until 10 June or until the AREO results are announced.

Bison Resources has appointed Tim Mackellar as CEO, leveraging his senior mining and capital markets experience to drive exploration and development efforts.

Little Green Pharma (ASX:LGP) has completed its merger with Cannatrek, creating a dominant player in Australia and Europe’s medicinal cannabis market with a majority stake held by former Cannatrek shareholders.

Raiz Invest announces a leadership change with Brendan Malone stepping down as CEO and Craig Keary taking over, signalling a new chapter for the fintech amid steady growth.

Third Age Health Services posted a 17.9% revenue increase and 24.7% profit rise for FY26, driven by strategic acquisitions and expansion in aged residential care services.

PolyNovo has completed its pivotal US clinical trial report for NovoSorb BTM and adjusted its FDA Premarket Approval submission timeline to late 2026 to incorporate updated regulatory requirements and additional data.

TradeWindow reported a 20% rise in FY26 revenue to NZ$9.6 million with annual recurring revenue surpassing NZ$10 million. The company narrowed its EBITDA loss and is targeting breakeven in FY27 while advancing its AI-driven FreightAI platform.

Select Harvests delivered a 33% rise in underlying NPAT despite a wet harvest and higher costs, announcing a fully franked interim dividend and a 10% on-market share buy-back.